The designation is a result of UNEEG's strong focus on developing novel disease management support tools with transformational and first-to-market...
DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November 25, 2024...
Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)Primary analysis data in potentially pivotal GBM...
CHAGRIN FALLS, OH / ACCESSWIRE / November 25, 2024 / S4 Medical Corp, an Ohio based company committed to making...
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Acreage Holdings, Inc. ("Acreage" or the "Company") (CSE:ACRG.A.U, ACRG.B.U)(OTCQX:ACRHF, ACRDF),...
CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming...
New artificial intelligence (AI) capabilities help hospitals and health systems deliver safer and more efficient care Teladoc Health's AI-enabled Virtual...
MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH)...
LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses...
Revenue Growth and APA Recognition Drive Momentum for QHSLab in 2024 WEST PALM BEACH, FL, Nov. 25, 2024 (GLOBE NEWSWIRE)...
Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS...
TN-401 AAV9-based Gene Therapy Designed to Deliver Fully Functional PKP2 Gene with the Aim of Increasing Protein Levels to Address...
VANCOUVER, Washington, Nov. 25, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing...
HAIFA, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a biotechnology...
CAMBRIDGE, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics, Inc. (Nasdaq: ERNA), a leader in cell therapies, today announced...
ST. LOUIS and SHANGHAI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd....
FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule,...
Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial ExecutionCORAL GABLES, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Catalyst...
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for...
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...